Features of 500 patients and survival from relapse
| Features . | Total no. . | Survival from relapse . | Log-rank Pvalue . | |
|---|---|---|---|---|
| Median years . | At 5 y (%) . | |||
| Interval from Dx to SCT | ||||
| <2 yr | 345 | 2.7 | 40 | =.001 |
| ≥2 yr | 155 | 1.7 | 23 | |
| Disease phase at SCT | ||||
| 1st CP | 315 | 4.3 | 46 | <.001 |
| >1st CP | 184 | 0.4 | 15 | |
| Donor type | ||||
| SIB | 466 | 2.4 | 36 | <.001 |
| VUD | 34 | 0.4 | 14 | |
| Patient sex | ||||
| Male | 297 | 2.1 | 32 | >.10 |
| Female | 201 | 2.3 | 37 | |
| R/D gender combination | ||||
| Male/female | 98 | 2.5 | 37 | >.10 |
| Other | 391 | 2.1 | 34 | |
| T-cell depleted SCT | ||||
| Yes | 228 | 2.7 | 37 | >.10 |
| No | 207 | 1.5 | 36 | |
| Acute GvHD* | ||||
| No | 233 | 2.5 | 36 | >.10 |
| Yes | 246 | 1.7 | 36 | |
| Grade of acute GvHD* | ||||
| 0 | 233 | 2.5 | 35 | >.10 |
| I | 139 | 2.0 | 34 | |
| ≥II | 107 | 1.5 | 38 | |
| Chronic GvHD* | ||||
| No | 277 | 2.9 | 39 | >.10 |
| Yes | 138 | 2.7 | 42 | |
| Patient age at relapse | ||||
| <35 yr | 223 | 1.7 | 35 | >.10 |
| ≥35 yr | 277 | 2.1 | 34 | |
| Interval from SCT to relapse | ||||
| <1 yr | 254 | 0.6 | 23 | <.001 |
| ≥1 yr | 246 | 4.3 | 57 | |
| Disease stage at relapse | ||||
| CYT or HCP | 308 | 4.4 | 47 | <.001 |
| HAP | 136 | 0.4 | 7 | |
| Date of relapse | ||||
| <1/1/90 | 283 | 2.5 | 35 | >.10 |
| ≥1/1/90 | 217 | 1.7 | 34 | |
| Total | 500 | 2.1 | 34 | |
| Features . | Total no. . | Survival from relapse . | Log-rank Pvalue . | |
|---|---|---|---|---|
| Median years . | At 5 y (%) . | |||
| Interval from Dx to SCT | ||||
| <2 yr | 345 | 2.7 | 40 | =.001 |
| ≥2 yr | 155 | 1.7 | 23 | |
| Disease phase at SCT | ||||
| 1st CP | 315 | 4.3 | 46 | <.001 |
| >1st CP | 184 | 0.4 | 15 | |
| Donor type | ||||
| SIB | 466 | 2.4 | 36 | <.001 |
| VUD | 34 | 0.4 | 14 | |
| Patient sex | ||||
| Male | 297 | 2.1 | 32 | >.10 |
| Female | 201 | 2.3 | 37 | |
| R/D gender combination | ||||
| Male/female | 98 | 2.5 | 37 | >.10 |
| Other | 391 | 2.1 | 34 | |
| T-cell depleted SCT | ||||
| Yes | 228 | 2.7 | 37 | >.10 |
| No | 207 | 1.5 | 36 | |
| Acute GvHD* | ||||
| No | 233 | 2.5 | 36 | >.10 |
| Yes | 246 | 1.7 | 36 | |
| Grade of acute GvHD* | ||||
| 0 | 233 | 2.5 | 35 | >.10 |
| I | 139 | 2.0 | 34 | |
| ≥II | 107 | 1.5 | 38 | |
| Chronic GvHD* | ||||
| No | 277 | 2.9 | 39 | >.10 |
| Yes | 138 | 2.7 | 42 | |
| Patient age at relapse | ||||
| <35 yr | 223 | 1.7 | 35 | >.10 |
| ≥35 yr | 277 | 2.1 | 34 | |
| Interval from SCT to relapse | ||||
| <1 yr | 254 | 0.6 | 23 | <.001 |
| ≥1 yr | 246 | 4.3 | 57 | |
| Disease stage at relapse | ||||
| CYT or HCP | 308 | 4.4 | 47 | <.001 |
| HAP | 136 | 0.4 | 7 | |
| Date of relapse | ||||
| <1/1/90 | 283 | 2.5 | 35 | >.10 |
| ≥1/1/90 | 217 | 1.7 | 34 | |
| Total | 500 | 2.1 | 34 | |
Dx indicates initial diagnosis; SCT, stem cell transplantation; CP, chronic phase; SIB, HLA-identical sibling; VUD, volunteer unrelated donor; R/D, recipient/donor; GvHD, graft-versus-host disease; CYT, cytogenetic relapse; HCP, hematologic relapse in CP; HAP, hematologic relapse in advanced phase (ie, accelerated phase or blastic phase).
Before the date of relapse.